Designing and Interpreting Coronavirus Disease 2019 (COVID-19) Diagnostics: Mathematics, Visual Logistics, and Low Prevalence
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Context.—: Coronavirus infectious disease-19 (COVID-19) diagnostics require understanding of how predictive values depend on sensitivity, specificity, and especially, low prevalence. Clear expectations, high sensitivity and specificity, and manufacturer disclosure will facilitate excellence of tests. Objectives.—: To derive mathematical equations for designing and interpreting COVID-19 tests, assess US Food and Drug Administration (FDA) Emergency Use Authorization and Health Canada minimum requirements, establish sensitivity and specificity tiers, and enhance clinical performance in low prevalence settings. Design.—: PubMed and other sources generated articles on COVID-19 testing and prevalence. EndNote X9.1 consolidated references. Mathematica and open access software helped prove equations, perform recursive calculations, graph multivariate relationships, and visualize patterns, including a new relationship, predictive value geometric mean-squared. Results.—: Derived equations were used to illustrate shortcomings of COVID-19 diagnostics in low prevalence. Visual logistics helped establish sensitivity/specificity tiers. FDA/Canada's 90% sensitivity, 95% specificity minimum requirements generate excessive false positives at low prevalence. False positives exceed true positives at prevalence lower than 5.3%, or if sensitivity is improved to 100% and specificity to 98%, at prevalence lower than 2%. Recursive testing improves predictive value. Three tiers emerged from these results. With 100% sensitivity, physicians can select desired predictive values, then input local prevalence, to determine suitable specificity. Conclusions.—: Understanding low prevalence impact will help health care providers meet COVID-19 needs for effective testing. Laypersons should receive clinical performance disclosure when submitting specimens. Home testing needs to meet the same high standards as other tests. In the long run, it will be more cost-effective to improve COVID-19 point-of-care tests rather than repeat testing multiple times.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PB analysis indicates that, in order to avoid spreading disease with false negatives, RAgTs should achieve an initial sensitivity of at least 91.0 -91.4 % [76, 77] and Tier-3 speci fi city of ≥ 99 %.”
From Point-of-care testing: state-of-the art and perspectives (2025) · cites this paper as [76]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tiered sensitivity/speci fi city comprise: Tier-1) 90 %, 95 %; Tier-2) 95 %, 97.5 %; and Tier-3) 100 %, ≥ 99 %, respectively [74 -77].”
From Point-of-care testing: state-of-the art and perspectives (2025) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
To, K. K.-W., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C.-Y., Cai, J.-P., Chan, J. M.-C., Chik, T. S.-H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,066
Laboratory Diagnosis of COVID-19: Current Issues and Challenges
Tang, Y.-W., Schmitz, J. E., Persing, D. H., & Stratton, C. W. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00512-20 · Cited by 1,232
Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19
Gao, Y., Li, T., Han, M., Li, X., Wu, D., Xu, Y., Zhu, Y., Liu, Y., Wang, X., & Wang, L. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25770 · Cited by 1,047
Evidence-based Medicine: How to Practice and Teach EBM
Satya-Murti, S. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550020100049 · Cited by 975
Mathematical models of infectious disease transmission
Grassly, N. C., & Fraser, C. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1845 · Cited by 744
COVID-19 antibody seroprevalence in santa clara county, california
Bendavid, E., Mulaney, B., Sood, N., Shah, S., Bromley-Dulfano, R., Lai, C., Weissberg, Z., Saavedra-Walker, R., Tedrow, J., Bogan, A., et al. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab010 · Cited by 669
COVID-19 Antibody Seroprevalence in Santa Clara County, CaliforniaPreprint
Bendavid, E., Mulaney, B., Sood, N., et al. (2020) · medRxiv · doi:10.1101/2020.04.14.20062463 · Cited by 559
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China
Xu, X., Sun, J., Nie, S., Li, H., Kong, Y., Liang, M., Hou, J., Huang, X., Li, D., Ma, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0949-6 · Cited by 405
Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources
Abdalhamid, B., Bilder, C. R., McCutchen, E. L., Hinrichs, S. H., Koepsell, S. A., & Iwen, P. C. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa064 · Cited by 322
Sample Pooling as a Strategy to Detect Community Transmission of SARS-CoV-2
Hogan, C. A., Sahoo, M. K., & Pinsky, B. A. (2020) · JAMA · doi:10.1001/jama.2020.5445 · Cited by 312
Research works printed but not linked: 13
- Calfas J. California mandates masks as cases climb. Wall Street Journal. 2020; 275(143): A7.
- Pence M. There isn't a Coronavirus ‘second wave.' Wall Street Journal . 2020; 275(141): A19.
- Galston W. Test every American for COVID-19. Wall Street Journal. 2020; 276(30): A15.
- Palazzalo J, West MG, Vielkind J, Berger P. New York response worsened the pandemic. Wall Street Journal. 2020; 275(137): A1, A8, A9.
- Hua S. New outbreak of virus cases rattles Beijing. Wall Street Journal. 2020; 273(140): A1, A8.
- Ansari T. Virus cases hit records in many states. Wall Street Journal. 2020; 275(147): A1, A6.
- Abbott B, Marcus AD . Race is on to devise fast at-home tests. Wall Street Journal. 2020; 275(123): A4.
- Scott CL . At-home testing arrives with accuracy and access questions. Wall Street Journal. 2020; 275(129): A9.
- Krouse S. Small business grapples with Covid testing. Wall Street Journal. 2020; 275(144): B1, B6.
- Kost GJ, Zhou Y, Katip P. Understanding point of care culture improves resilience and standards of care in limited-resource countries. In:Kost GJ, ed, Curtis CM, assoc ed. Global Point of Care: Strategies for Disasters, Emergencies, and Public Health Preparedness. Washington, DC: AACC Press-Elsevier;2015: 471– 490.
- Magalhaes L, Forero J. Latin America is pandemic's grim new center. Wall Street Journal. 2020; 275(147): A8.
- Rashid ZZ, Othman SN, Samat MNA, Ali UK, Wong KK . Diagnostic performance of COVBID-19 serology assays. Malaysian J Pathol. 2020; 42(1): 13– 21.
- Kost GJ, Ferguson WJ, Truong A-T, et al. The Ebola Spatial Care PathTM: point-of-care lessons learned for stopping outbreaks. Clin Lab Int. 2015; 39: 6– 14.
Cited by
Point-of-care testing: state-of-the art and perspectives
Plebani, M., Nichols, J. H., Luppa, P. B., Greene, D., Sciacovelli, L., Shaw, J., Khan, A. I., Carraro, P., Freckmann, G., Dimech, W., et al. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-0675 · Cited by 119
Self-citationFavresse, J., Gillot, C., Oliveira, M., Cadrobbi, J., Elsen, M., Eucher, C., Laffineur, K., Rosseels, C., Eeckhoudt, S. V., Nicolas, J., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020265 · Cited by 83
Point-of-Care Testing—The Key in the Battle against SARS-CoV-2 Pandemic
Iliescu, F. S., Ionescu, A. M., Gogianu, L., Simion, M., Dediu, V., Chifiriuc, M. C., Pîrcălăbioru, G. G., & Iliescu, C. (2021) · Micromachines · doi:10.3390/mi12121464 · Cited by 38
Kost, G. J. (2021) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0716-sa · Cited by 23
Self-citationDiagnostic Strategies for Endemic Coronavirus Disease 2019 (COVID-19)
Kost, G. J. (2022) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0386-sa · Cited by 22
Self-citation
Metadata
- Authors
- Kost, G. J.
- Affiliations
- University of California, Davis (US)
- Corresponding author
- Kost, Gerald J.
- ORCID
- Kost, Gerald J.
- Venue
- Archives of Pathology & Laboratory Medicine
- Published
- 2020-09-09
- Volume
- 145
- Issue
- 3
- Pages
- 291-307
- ISSN
- 0003-9985 (ISSN-L)
- 1543-2165
- OpenAlex
- W3083810684
- Cited by
- 9
- References
- 34
- Citations by year
- 2024: 2 · 2023: 1 · 2022: 1 · 2021: 5
- FWCI
- 0.23
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- public-domain
- Locations
- Archives of Pathology & Laboratory Medicine (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- COVID-19 diagnosis, diagnostic test sensitivity and specificity, low prevalence, predictive value, false positives, FDA emergency use authorization, point-of-care testing, home testing
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Testing, Algorithms, Humans, Models, Theoretical, Research Design, Sensitivity and Specificity, Reproducibility of Results, Prevalence, Epidemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Designing and Interpreting Coronavirus Disease 2019 (COVID-19) Diagnostics: Mathematics, Visual Logistics, and Low Prevalence. https://app.cochat.ai/papers/10.5858/arpa.2020-0443-sa
- The paper
- Kost, G. J. (2021). Designing and Interpreting Coronavirus Disease 2019 (COVID-19) Diagnostics: Mathematics, Visual Logistics, and Low Prevalence. Archives of Pathology & Laboratory Medicine. https://doi.org/10.5858/arpa.2020-0443-sa
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.